Alimta® (pemetrexed) – New warnings

- On October 11, 2017, the FDA approved updates to the *Warnings and Precautions* section of the Alimta (pemetrexed) drug label.

- Alimta is indicated for the following:

    - Initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin.
    - Maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as a single agent.
    - Treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy, as a single agent.
    - In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

- Information regarding myelosuppression and increased risk of myelosuppression without vitamin supplementation, renal failure, bullous and exfoliative skin toxicity, interstitial pneumonitis, radiation recall, and increased risk of toxicity with ibuprofen in patients with renal impairment were added to the *Warnings and Precautions* section of the Alimta drug label.

- The Alimta drug label was also updated to conform to the Pregnancy and Lactation Labeling Rule consistent with FDA Draft Guidance for Industry.

- Refer to the Alimta drug label for more details regarding the updates.